Skip To Content

Participating in open and frank conversations can be a catalyst for both positive change and a better industry. As we share our perspective you will find:

  • Relevant and timely industry information
  • Medication trends, and their impact
  • Case studies, and the results of their related projects
  • Special-subject on-demand webinars

Articles and blogs 

Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.

November 24, 2020 · Clinical Team
The U.S. Food and Drug Administration (FDA) authorized the use of the Lucira™ COVID-19 All-In-One Test Kit under an Emergency Use Authorization (EUA) on November 17, 2020.  This is the first at-home nasal swab test kit to detect SARS-CoV-2  the virus that causes the coronavirus disease 2019 (COVID-19). Read more...
November 23, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
November 18, 2020 · Public Policy & Regulatory Affairs Team
The New York Workers’ Compensation Board (WCB) has temporarily suspended application of drug formulary refill/renewal requirements, moving them from January 1, 2021, to an undetermined date at this time. Read more...
November 05, 2020 · Optum Workers' Comp and Auto No-fault
During the recent National Alliance of Medicare Set-Aside Professionals (NAMSAP), now known as the National Medicare Secondary Payer Network, annual conference, John Jenkins, Health Insurance Specialist, Division of Medicare Secondary Payer Program Operations, Office of Financial Management for the Centers for Medicare and Medicaid Services (CMS) provided information on the appropriate method for calculating seed money for annuities involving a Workers’ Compensation Medicare Set-Aside (WCMSA) within the total settlement amount. Read more...
November 03, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
October 30, 2020 · Clinical Team
Evzio auto-injector and naloxone auto-injector have been discontinued and will no longer be available, according to kaléo Inc. (kaléo). According to information Optum has obtained from kaléo, previously dispensed Evzio and its authorized generic are still safe to use until their expiration dates. In addition, pharmacies may dispense current stock, but future refills will not likely be available. Read more...
     Next >>
Page 1 of 17

Subscribe today to receive our latest blogs, articles and more.